; neutrophil count 10.6 Â 10 9 L -1 ) 46 days after his most recent BPG injection. On admission, he was administered 900 mg (2.3 ml) intramuscular BPG (Bicillin L-A) to the right gluteal region as a scheduled dose of secondary prophylaxis. Two days later, echocardiography and magnetic resonance imaging (MRI) of the left hip were performed.
MRI revealed a small left hip effusion consistent with acute arthritis, but no evidence of osteomyelitis. An unexpected finding on MRI was extensive inflammatory change within the right gluteus maximus, corresponding to the site of the BPG injection ( Fig. 1 ). Findings were consistent with myositis, likely secondary to local inflammatory reaction to BPG.
Echocardiography demonstrated carditis with progression of RHD (moderate mitral regurgitation, moderate aortic regurgitation). Left hip pain responded promptly to oral aspirin, but the child had significant injection-site pain and an associated limp for a further 5 days.
Intramuscular BPG is crucial in the management and secondary prevention of ARF and RHD. The injection is painful, and as demonstrated in this case, can result in significant local inflammation. These complications may be influenced by poor injection technique or product quality, but neither of these are likely in our setting. Poor adherence to BPG hampers the success of RHD programmes throughout the world. Further research into the impact of adverse effects would be informative. Improved delivery systems for long-acting prophylactic penicillin in the secondary prevention of RHD are desperately needed. A 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in the context of secondary prophylaxis for rheumatic heart disease. Side effects of intramuscular delivery of benzathine penicillin-G are well described and include injection site pain and inflammation, but myositis, as depicted on magnetic resonance imaging in this case, has not previously been described. 
